The FDA is phasing out animal testing and moving to more human-relevant methods. This was announced as one of Marty Makary’s ...

In this interview, rare disease expert Oxana Iliach discusses challenges with rare disease drug development and how they can ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

The announcement comes amid ongoing discussions about the efficiency and transparency of the FDA’s drug approval process ... the company has initiated a Phase III clinical study of Bysanti ...

The FDA has responded to the increasing use of artificial intelligence (AI) in the discovery and development of drugs and biologics ... early on in the development process to get feedback on ...

Presentations at WHS and SAWC to highlight EscharEx's mechanism of action, preclinical advantages over SANTYL®, and new data in treating V ...

Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-T) from The Globe and Mail including charting and trades.

Pfizer is deeply undervalued, and has a high dividend yield, and I see tons of institutions and analysts buying the dip. Read ...

Despite more treatment options being a positive, Ben Hargreaves finds that this has raised issues over single-region clinical trials, leading to the FDA ... to the drug development process.

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted ... ZL-1310 received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in January 2025, recognizing its ...